Live Breaking News & Updates on Cara Therapeutic

Stay updated with breaking news from Cara therapeutic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Brokers Offer Predictions for Cara Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:CARA)

Cara Therapeutics, Inc. (NASDAQ:CARA – Free Report) – Equities researchers at HC Wainwright lifted their Q2 2024 earnings per share estimates for shares of Cara Therapeutics in a note issued to investors on Wednesday, May 15th. HC Wainwright analyst O. Livnat now expects that the biopharmaceutical company will post earnings per share of ($0.22) for […] ....

United States , Needham Company , Algert Global , Marquette Asset Management , Cara Therapeutics Inc , Mackenzie Financial Corp , Canaccord Genuity Group , Sg Americas Securities , Cara Therapeutics , Free Report , Cara Therapeutic , Genuity Group , Therapeutics Stock Down , Get Free Report , Financial Corp , Cara Therapeutics Daily ,

We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although. ....

How Well Is Cara Therapeutics , Cara Therapeutic , Cara Therapeutics , Free Cash Flow ,

Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis

– Oral difelikefalin as adjunct to topical corticosteroids did not demonstrate meaningful clinical benefit compared to TCS alone; As a result, Cara will discontinue its clinical program in pruritus. ....

Iris Francesconi , Annie Spinetta , Joana Goncalves , Cara Therapeutics Inc , Company Annual Report On Form , Exchange Commission , Chief Medical Officer , Healthcare Royalty , Private Securities Litigation Reform Act , Cara Therapeutic , Annual Report ,

Cara Therapeutics Reports Third Quarter 2023 Financial

– Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025 – – Key data readouts for all. ....

Harrisonm Bains , Helenm Boudreau , Iris Francesconi , Annie Spinetta , Christopher Posner , Development Rd Expenses , Enteris Biopharma Inc , Centers For Medicare Medicaid Services , Maruishi Pharmaceuticals Co , Exchange Commission , Company Board Of Directors , Audit Committee , Cara Therapeutics Inc , Company Annual Report On Form , Neuropathic Itch Patient Survey , Healthcare Royalty , Chief Executive Officer , Royalty Interest Purchase , Sale Agreement , Medicaid Services , Stage Renal Disease Prospective Payment System , Healthcare Conference , London Healthcare Conference , Sandler Healthcare Conference , Maruishi Pharmaceuticals , Goods Sold ,

Cara Therapeutics Reports Third Quarter 2023 Financial Results

– Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025– ....

Helenm Boudreau , Harrisonm Bains , Annie Spinetta , Christopher Posner , Iris Francesconi , Cara Therapeutics Inc , Development Rd Expenses , Maruishi Pharmaceuticals Co , Company Annual Report On Form , Exchange Commission , Company Board Of Directors , Enteris Biopharma Inc , Neuropathic Itch Patient Survey , Audit Committee , Centers For Medicare Medicaid Services , Healthcare Royalty , Chief Executive Officer , Royalty Interest Purchase , Sale Agreement , Medicaid Services , Stage Renal Disease Prospective Payment System , Healthcare Conference , London Healthcare Conference , Sandler Healthcare Conference , Maruishi Pharmaceuticals , Goods Sold ,